Amelioration of colitis progression by ginseng-derived exosome-like nanoparticles through suppression of inflammatory cytokines.
Exosomes
Ginseng-derived exosomes-like nanoparticles
Inflammatory bowel disease (IBD)
Panax Ginseng
Plant-derived exosome-like nanoparticles
Journal
Journal of ginseng research
ISSN: 1226-8453
Titre abrégé: J Ginseng Res
Pays: Korea (South)
ID NLM: 100890690
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
15
07
2022
revised:
10
11
2022
accepted:
05
01
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
ppublish
Résumé
Damage to the healthy intestinal epithelial layer and regulation of the intestinal immune system, closely interrelated, are considered pivotal parts of the curative treatment for inflammatory bowel disease (IBD). Plant-based diets and phytochemicals can support the immune microenvironment in the intestinal epithelial barrier for a balanced immune system by improving the intestinal microecological balance and may have therapeutic potential in colitis. However, there have been only a few reports on the therapeutic potential of plant-derived exosome-like nanoparticles (PENs) and the underlying mechanism in colitis. This study aimed to assess the therapeutic effect of PENs from To evaluate the anti-inflammatory effect of GENs on acute colitis, we treated GENs in Caco2 and lipopolysaccharide (LPS) -induced RAW 264.7 macrophages and analyzed the gene expression of pro-inflammatory cytokines and anti-inflammatory cytokines such as TNF-α, IL-6, and IL-10 by real-time PCR (RT-PCR). Furthermore, we further examined bacterial DNA from feces and determined the alteration of gut microbiota composition in DSS-induced colitis mice after administration of GENs through 16S rRNA gene sequencing analysis. GENs with low toxicity showed a long-lasting intestinal retention effect for 48 h, which could lead to effective suppression of pro-inflammatory cytokines such as TNF-α and IL-6 production through inhibition of NF-κB in DSS-induced colitis. As a result, it showed longer colon length and suppressed thickening of the colon wall in the mice treated with GENs. Due to the amelioration of the progression of DSS-induced colitis with GENs treatment, the prolonged survival rate was observed for 17 days compared to 9 days in the PBS-treated group. In the gut microbiota analysis, the ratio of Firmicutes/Bacteroidota was decreased, which means GENs have therapeutic effectiveness against IBD. Ingesting GENs would be expected to slow colitis progression, strengthen the gut microbiota, and maintain gut homeostasis by preventing bacterial dysbiosis. GENs have a therapeutic effect on colitis through modulation of the intestinal microbiota and immune microenvironment. GENs not only ameliorate the inflammation in the damaged intestine by downregulating pro-inflammatory cytokines but also help balance the microbiota on the intestinal barrier and thereby improve the digestive system.
Sections du résumé
Background
UNASSIGNED
Damage to the healthy intestinal epithelial layer and regulation of the intestinal immune system, closely interrelated, are considered pivotal parts of the curative treatment for inflammatory bowel disease (IBD). Plant-based diets and phytochemicals can support the immune microenvironment in the intestinal epithelial barrier for a balanced immune system by improving the intestinal microecological balance and may have therapeutic potential in colitis. However, there have been only a few reports on the therapeutic potential of plant-derived exosome-like nanoparticles (PENs) and the underlying mechanism in colitis. This study aimed to assess the therapeutic effect of PENs from
Method
UNASSIGNED
To evaluate the anti-inflammatory effect of GENs on acute colitis, we treated GENs in Caco2 and lipopolysaccharide (LPS) -induced RAW 264.7 macrophages and analyzed the gene expression of pro-inflammatory cytokines and anti-inflammatory cytokines such as TNF-α, IL-6, and IL-10 by real-time PCR (RT-PCR). Furthermore, we further examined bacterial DNA from feces and determined the alteration of gut microbiota composition in DSS-induced colitis mice after administration of GENs through 16S rRNA gene sequencing analysis.
Result
UNASSIGNED
GENs with low toxicity showed a long-lasting intestinal retention effect for 48 h, which could lead to effective suppression of pro-inflammatory cytokines such as TNF-α and IL-6 production through inhibition of NF-κB in DSS-induced colitis. As a result, it showed longer colon length and suppressed thickening of the colon wall in the mice treated with GENs. Due to the amelioration of the progression of DSS-induced colitis with GENs treatment, the prolonged survival rate was observed for 17 days compared to 9 days in the PBS-treated group. In the gut microbiota analysis, the ratio of Firmicutes/Bacteroidota was decreased, which means GENs have therapeutic effectiveness against IBD. Ingesting GENs would be expected to slow colitis progression, strengthen the gut microbiota, and maintain gut homeostasis by preventing bacterial dysbiosis.
Conclusion
UNASSIGNED
GENs have a therapeutic effect on colitis through modulation of the intestinal microbiota and immune microenvironment. GENs not only ameliorate the inflammation in the damaged intestine by downregulating pro-inflammatory cytokines but also help balance the microbiota on the intestinal barrier and thereby improve the digestive system.
Identifiants
pubmed: 37720571
doi: 10.1016/j.jgr.2023.01.004
pii: S1226-8453(23)00004-0
pmc: PMC10499592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
627-637Informations de copyright
© 2023 The Korean Society of Ginseng. Publishing services by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12672-12677
pubmed: 31182571
Acta Pharmacol Sin. 2021 Sep;42(9):1461-1471
pubmed: 33268823
Immunobiology. 2013 Dec;218(12):1452-67
pubmed: 23735482
MMWR Morb Mortal Wkly Rep. 2016 Oct 28;65(42):1166-1169
pubmed: 27787492
Nutrients. 2019 Nov 15;11(11):
pubmed: 31731808
Cell Host Microbe. 2018 Nov 14;24(5):637-652.e8
pubmed: 30449315
World J Stem Cells. 2020 Oct 26;12(10):1050-1066
pubmed: 33178391
J Agric Food Chem. 2010 Jan 27;58(2):868-74
pubmed: 20030409
Front Mol Neurosci. 2015 Jun 16;8:24
pubmed: 26136655
World J Gastroenterol. 2014 Aug 7;20(29):9675-90
pubmed: 25110407
J Neuroimmunol. 2001 Feb 1;113(1):49-62
pubmed: 11137576
Mol Nutr Food Res. 2014 Jul;58(7):1561-73
pubmed: 24842810
Biomaterials. 2021 Dec;279:121178
pubmed: 34656857
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
J Microbiol. 2008 Dec;46(6):737-43
pubmed: 19107405
Clin Exp Immunol. 2004 Jan;135(1):64-73
pubmed: 14678266
J Ginseng Res. 2022 Jan;46(1):54-61
pubmed: 35058727
J Exp Med. 2010 Dec 20;207(13):2843-54
pubmed: 21098096
Front Cell Neurosci. 2020 Mar 20;14:55
pubmed: 32265659
Lab Invest. 1993 Aug;69(2):238-49
pubmed: 8350599
Neuron. 2015 Feb 4;85(3):534-48
pubmed: 25619654
Methods Mol Biol. 1994;32:9-15
pubmed: 7951753
Mol Ther. 2017 Jul 5;25(7):1641-1654
pubmed: 28274798
J Ginseng Res. 2018 Jul;42(3):255-263
pubmed: 29983606
Cell Res. 2020 Jun;30(6):492-506
pubmed: 32433595
Gut. 2021 Jul;70(7):1396-1405
pubmed: 33431575
Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43
pubmed: 20485259
Int J Mol Sci. 2015 Apr 02;16(4):7493-519
pubmed: 25849657
Am J Chin Med. 2017;45(1):13-22
pubmed: 28068835
Cells. 2022 Jan 23;11(3):
pubmed: 35159192
Nano Lett. 2021 Oct 13;21(19):8151-8159
pubmed: 34586821
PLoS One. 2013 Nov 18;8(11):e79445
pubmed: 24260222
Front Pharmacol. 2021 Apr 14;12:651415
pubmed: 33935763
J Ginseng Res. 2021 Nov;45(6):617-630
pubmed: 34764717
World J Gastroenterol. 2014 Jun 7;20(21):6374-85
pubmed: 24914359
J Ginseng Res. 2017 Oct;41(4):435-443
pubmed: 29021688
J Ginseng Res. 2018 Jul;42(3):239-247
pubmed: 29989012
Sci Rep. 2018 Oct 2;8(1):14644
pubmed: 30279553
Microorganisms. 2020 Nov 01;8(11):
pubmed: 33139627
PLoS One. 2016 Jan 04;11(1):e0146162
pubmed: 26727498
J Ginseng Res. 2018 Jul;42(3):248-254
pubmed: 29983605
J Extracell Vesicles. 2015 Nov 25;4:28713
pubmed: 26610593
World J Gastroenterol. 2005 Sep 7;11(33):5185-92
pubmed: 16127750
Cancer Prev Res (Phila). 2016 Oct;9(10):803-811
pubmed: 27443884
J Ginseng Res. 2022 May;46(3):481-488
pubmed: 35600766
Front Immunol. 2019 Apr 09;10:705
pubmed: 31024544
J Ginseng Res. 2022 Mar;46(2):235-247
pubmed: 35509823
Nat Commun. 2013;4:1867
pubmed: 23695661
J Immunol. 2004 Sep 15;173(6):4137-46
pubmed: 15356164
J Ginseng Res. 2022 May;46(3):426-434
pubmed: 35600772
Front Med (Lausanne). 2021 Jun 25;8:651685
pubmed: 34249960
J Control Release. 2020 Jan 10;317:259-272
pubmed: 31783047
Immunol Invest. 2016 Jul;45(5):439-49
pubmed: 27224660
Front Aging Neurosci. 2015 Jul 16;7:129
pubmed: 26236231